Pharma BD Deal Intelligence
Genentech's $850M upfront grab of Regor's RGT-419B was a targeted post-CDK4/6 bet against Ibrance, Verzenio, and Kisqali, and it's paying off early: SABCS 2025 first-in-human data showed 4 confirmed PRs among 24 evaluable patients, though pivotal proof is still pending.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche turns to a startup in search for new breast cancer drugs, agreeing to pay $850 million upfront for Regor Pharmaceuticals' CDK inhibitor portfolio. The…
Genentech buys Regor's CDK inhibitors in an $850 million deal, acquiring rights to the next-generation CDK4/2 inhibitor RGT-419B for HR+/HER2- metastatic…
SABCS 2025 (Dec 9-12, 2025) first-in-human Phase 1a/b of GDC-4198 (RGT-419B), a next-generation CDK4/2 inhibitor, in HR+/HER2- LA/mBC progressed on prior…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Regor entered definitive purchase agreement for Genentech (Roche subsidiary) to acquire Regor's portfolio of next-generation CDK inhibitors including RGT-419B (CDK2-active) for HR+/HER2- advanced/metastatic breast cancer. $850M upfront plus development, regulatory, and commercial milestones. Positions Roche to compete against Ibrance/Verzenio/Kisqali franchise. UPDATE (reviewed 2026-06): The acquisition completed in Q4 2024 (Roche Holdings Inc. 2024 Annual Report; USD 0.9B recognized as intangible assets), and the lead asset RGT-419B was rebranded GDC-4198 (RO7840734) under Genentech. Genentech opened a randomized Phase 1b/2 trial (NCT07100106, start Oct 2025) testing GDC-4198 +/- giredestrant against abemaciclib + giredestrant in the post-CDK4/6 setting, and SABCS 2025 first-in-human data showed single-agent activity (4 confirmed PRs / 24 evaluable patients) with good tolerability - confirming the post-CDK4/6 resistance thesis that drove the deal.
200K US cases/yr · $17.6B Global CDK4/6 inhibitor class 2026E sales (Towards Healthcare / DelveInsight) · 5300 Pfizer Ibrance FY2024 global net sales (USD MM) - class leader reference
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common breast cancer subtype, accounting for roughly 65-70% of all breast cancers diagnosed in the United States. Per American Cancer Society 2024 estimates, approximately 310,720 new invasive breast cancer cases occurred in US women, translating to ~200,000+ HR+/HER2- incident cases, of which 20-30% will eventually develop metastatic disease. The modern first-line metastatic HR+/HER2- standard of care combines a CDK4/6 inhibitor (palbociclib/Ibrance, abemaciclib/Verzenio, or ribociclib/Kisqali) with an aromatase inhibitor or fulvestrant - a regimen that has extended median progression-free survival to ~25-30 months and reshaped the multi-billion-dollar class. Despite initial efficacy, virtually all patients develop resistance, driven in part by compensatory CDK2 signaling, ESR1 mutations, and PI3K/AKT pathway activation. Post-CDK4/6 treatment options include elacestrant (Orserdu, Stemline/Menarini) for ESR1-mutant disease, PI3K/AKT inhibitors, and antibody-drug conjugates such as Trodelvy and Enhertu. Next-generation CDK2 and CDK2/4 inhibitors represent a rational strategy to extend cell-cycle blockade into the post-CDK4/6 space, which is the rationale behind Genentech's acquisition of Regor's RGT-419B program.
The HR+/HER2- metastatic breast cancer landscape is anchored by three approved CDK4/6 inhibitors and a proliferating post-CDK4/6 resistance pipeline. CDK4/6 inhibitors (1L standard): palbociclib (Ibrance, Pfizer - 2024 sales ~$5.3B; ~70% class share), ribociclib (Kisqali, Novartis - ~$2.5B 2024, +65% YoY), abemaciclib (Verzenio, Eli Lilly - $5B+ 2024). SERDs and endocrine post-CDK4/6: elacestrant (Orserdu, Stemline/Menarini - ESR1 mutant), fulvestrant (Faslodex, AstraZeneca and generics), giredestrant (Roche Phase 3), imlunestrant (Lilly Phase 3). Targeted second-line: alpelisib (Piqray, Novartis - PIK3CA mutant), capivasertib (Truqap, AstraZeneca - AKT inhibitor, PTEN/PIK3CA/AKT1), inavolisib (Itovebi, Roche - PIK3CA-selective, 2024 approval). ADCs post-CDK4/6: trastuzumab deruxtecan (Enhertu, Daiichi/AZ - HER2-low label), sacituzumab govitecan (Trodelvy, Gilead - TROP2). Next-gen CDK inhibitors (the Regor thesis): RGT-419B (CDK2/4, Genentech), PF-07220060 (CDK4-selective, Pfizer), INX-315 and BLU-222 (CDK2-selective, Incyclix/Blueprint). Genentech's $850M upfront stakes Roche's post-CDK4/6 position through a mechanism that can combine with or follow Ibrance.
Roche Holdings Inc. 2024 Annual Report confirms the purchase of Regor's next-generation CDK inhibitor R&D portfolio completed during 2024, with the initial payment recognized as USD 0.9B of intangible assets. (Exact close day not disclosed; recorded as year-end 2024.)
Genentech-sponsored randomized Phase 1b/2 NCT07100106 begins, testing GDC-4198 (formerly RGT-419B) alone and with giredestrant vs abemaciclib + giredestrant in post-CDK4/6 HR+/HER2- advanced breast cancer.
First-in-human Phase 1a/b data (SABCS 2025) show GDC-4198 well tolerated with single-agent activity post-CDK4/6 (4 confirmed PRs / 24 evaluable monotherapy patients), supporting the resistance-breaking thesis behind the acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. (this deal) | 2024 | $850M | — |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
← Browse all deals · How we score deals
More: 2024 deals · Genentech, Inc. (Roche Group) deals · Oncology deals